November 11, 2019 / 6:24 AM / a month ago

BRIEF-Roche Presents Results Of Phase II Gazyva Study

Nov 11 (Reuters) - Roche Holding AG:

* ANNOUNCES DATA FROM PHASE II NOBILITY STUDY, INVESTIGATING THE SAFETY AND EFFICACY OF GAZYVA

* GAZYVA, IN COMBINATION WITH STANDARD OF CARE, MORE THAN DOUBLES PERCENTAGE OF LUPUS NEPHRITIS PATIENTS ACHIEVING COMPLETE RENAL RESPONSE, COMPARED TO STANDARD OF CARE ALONE Source text: bit.ly/34TeKX9 Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below